Multibodies – Attacking multiple pathways with a single, computationally-designed, antibody

Because of the complex and ever-changing natures of both cancer and the immune system, therapeutic approaches that focus on one protein rarely work for an extended period of time. This is why most clinical trials in immuno-oncology today explore combinations of two drugs. However, combination therapies present tremendous challenges, including the need to clinically validate each molecule on its own before exploring the effect of the combination. This makes clinical development even longer and more expensive than it usually is. It also hinders the study of truly synergistic combinations that may be toxic or ineffective on their own. We present an approach for the design of Multibodies, human antibodies that can precisely manipulate multiple pathway by specifically binding functional epitopes on more than one target. This approach may allow for the execution of novel and sophisticated molecular strategies.